Small-molecule inhibitors of Bcl-2

Current Opinion in Investigational Drugs

Volumn 7, Issue 12, 2006, Pages 1077-1084

  Manion, Michael K ^a   Fry, John ^a   Schwartz, Pam S ^a   Hockenbery, David M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Apoptosis; BH3; Chemoresistance; Mitochondria; Peptidomimetic

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 METHOXY ANTIMYCIN A; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; A 385358; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOGOSSYPOLONE; BENZAMIDE DERIVATIVE; BH3 PROTEIN; CHELERYTHRINE; CYTOTOXIC AGENT; EM 20 25; GOSSYPOL; GX 015 070; OBATOCLAX; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL 2 SMALL MOLECULE INHIBITOR; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; SANGUINARINE; THIAZOLIDINE DERIVATIVE;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ATAXIA; AZOOSPERMIA; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPHORIA; FOLLICULAR LYMPHOMA; GLIOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; INFERTILITY; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RACEMIC MIXTURE; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, MOLECULAR; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL;

EID: 33845638681     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 60(21):6101-6110.
2. L can confer a multidrug resistance phenotype. Blood (1995) 86(5):1903-1910.
3. Antonsson B, Martinou JC: The Bcl-2 protein family. Exp Cell Res (2000) 256(1):50-57.
4. Scorrano L, Korsmeyer SJ: Mechanisms of cytochrome C release by proapoptotic Bcl-2 family members. Biochem Biophys Res Commun (2003) 304(3):437-444.
5. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (1994) 369(6478):321-323.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC: Differential targeting of prosurvival Bol-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 17(3):393-403.
7. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A: Mitochodria primed by death signals determine cellular addiction to antiapoptotic Bcl-2 family members. Cancer Cell (2006) 9(5):351-365.
8. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res (1997) 57(1):62-67.
9. Cheng WC, Berman SB, Ivanovska I, Jonas EA, Lee SJ, Chen Y, Kaczmarek LK, Pineda F, Hardwick JM: Mitochondrial factors with dual roles In death and survival. Oncogene (2006) 25(34):4697-4705.
10. L regulates the membrane potential and volume homeostasis of mitochondria. Cell (1997) 91(5):627.637.
11. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G: Mitochondrial of nuclear apoptosis. J Exp Med (1996) 183(4):1533-1544.
12. Raff MC: Social controls on cell survival and cell death. Nature (1992) 356(6368):397-400.
13. Jiang M, Milner J: Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev (2003) 17(7):832-837.
14. Holle L, Hicks L, Song W, Helle E, Wagner T, Yu X: Bcl-2 targeting siRNA expressed by a T7 vector system inhibits human tumor growth in vitro. Int J Oncol (2004) 24(3):615-621.
15. Keith FJ, Bradbury DA, Zhu YM, Russell NH: Inhibition of Bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 9(1):131-138.
16. L-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst (2001) 93(6):463-471.
17. L antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer (2001) 94(2):268-274.
18. Dorai T, Perlman H, Walsh K, Shabsigh A, Goluboff ET, Olsson CA, Buttyan R: A recombinant defective adenoviral agent expressing and-Bcl-2 ribozyme promotes apoptosis of Bcl-2-expressing human prostate cancer cells. Int J Cancer (1999) 82(6):846-852.
19. Luzi E, Papucci L, Schiavone N, Donnini M, Lapucci A, Tempestini A, Witort E, Nicolin A, Capaccioli S: Downregulation of Bcl-2 expression In lymphoma cells by Bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther (2003) 10(3):201-208.
20. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK: Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell(2004) 116(4):527-540.
21. 1 cyclin-dependent kinases. Oncogene (2002) 21(51):7765-7775.
22. Schor NF, Rudin CM, Hartman AR, Thompson CB, Tyurina YY, Kagan VE: Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene (2000) 19(3):472-476.
23. Papas KK, Sun L, Roos ES, Gounarides JS, Shapiro M, Nalin CM: Change in lactate production in Myc-transformed cells precedes apoptosis and can be inhibited by Bcl-2 overexpression. FEBS Lett (1999) 446(2-3):338-342.
24. 2+ homeostatis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci USA (2002) 99(15):9830-9835.
25. Tzung SP, Kim KM, Basañez G, Giedt CD, Simon J, Zimmerberg J, Zhang KYJ, Hockenbery DM: Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol (2001) 3(2):183-191.
26. L, an inhibitor of programmed cell death. Nature (1996) 381(8580):335-341.
27. Xu X, Leo C, Jang Y, Chan E, Padilla D, Huang BC, Lin T, Gururaja T, Hitoshi Y, Lorens JB, Anderson DC et al: Dominant effector genetic in mammalian cells. Nat Genet (2001) 27(1):23-29.
28. Kay BK, Hamilton PT: Identification of enzyme inhibitors form phage-displayed combinatorial peptide libraries. Comb Chem High Throughput Screen (2001) 4(7):535-543.
29. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ: A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J (1995) 14(22):5589-5596.
30. L-Bak peptide complex: Recognition between regulators of apoptosis. Science (1997) 275(5302):983-986.
31. Dodou K, Anderson RJ, Small DA, Groundwater PW: Investigations on gossypol: Past and present developments. Expert Opin Investig Drugs (2005) 14(11):1419-1434.
32. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M: Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem (2003) 46(20):4259-4264.
33. Prade CE, Castro JE, Aguillon RA, Loria O, Zhai D, Kitada S, Reed JC, Kipps TJ: R-(-)-gossypol (AT-101) binds to Bcl-2 family proteins and induces apoptosis in CLL. Blood (2005) 106:Abs 2978.
34. Saleh M, Pitot H, Hartung J, Holmlund J, LoBuglio A, Forero A: Phase I trial of AT-101, an orally bioavailable inhibitor of Bcl-2, in patients with advanced malignacies. AACR NCI EORTC Mol Targets Cancer Ther (2005):Abs C89.
35. L. Chem Biol (2004) 11(3):389-395.
36. Shelley MD, Hartley L, Groundwater PW, Fish RG: Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs (2000) 11(3):209-216.
37. Yang D, Nikolovska-Coleoka Z, Chert J, Xu L, Gao W, Guo J, Qui S, Holmlund J, Sorensen M, Wang S: AT-101 and ApoG2, highly potent and orally active small molecule inhibitors of Mcl-1 protein and potential applications for apoptosis-targeted anticancer therapy. AACR NCI EORTC Mol Targets Cancer Ther (2005):Abs C223.
38. Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol (1992) 30(6):480-482.
39. Fleck MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal carcinoma. J Clin Endocrinol Metab (1993) 76(4):1019-1024.
40. Bushenow P, Reidenberg MM, Wasenko J, Winfield J, Lorenzo B, Lemke S, Himpler B, Corona R, Coyle T: Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol (1999) 43(1):79-86.
41. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R at al: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res Treat (2001) 66(3):239-248.
42. James DF, Castro JE, Loria O, Mervis RM, Aguillon R, Kipps TJ: AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL Patients with high-risk features; preliminary results from an ongoing phase I trial. J Clin Oncol (2006) 24(18S):Abs 6605.
43. Shore GC, Viallet J: Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am Soc Hematol Educ Program (2005):226-230.
44. O'Brien S, Kipps TJ, Faderi S, Crump M, Keating MJ, Anderson B, Soho C, Bole J, Turner R, Viallet J, Cheson BD: A phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (lv) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). Am Soc Hematol (2005) 47:Abs 446.
45. Wang JL, Liu D, Zhang Z J, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA (2000) 97(13):7124-7129.
46. An J, Chen Y, Huang Z: Critical upstream signals of cytochrome C release induced by a novel Bcl-2 Inhibitor. J Biol Chem (2004) 279(18):19133-19140.
47. Milanesi E, Costantini P, Gambalunga A, Colonna R, Petronilli V, Cabrelle A, Semenzato G, Cesura AM, Pinard E, Bernardi P: The mitochondrial effects of small organic ligands of Bcl-2: Sensitization of Bcl-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. J Biol Chem (2006) 281(15):10066-10072.
48. L. Nat Cell Biol (2001) 3(2):173-182.
49. Hennet T, Bertoni G, Richter C, Peterhans E: Expression of Bcl-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res (1993) 53(6):1456-1460.
50. L mutations suppress cellular sensitivity to antimycin A. J Biol Chem (2004) 279(3):2159-2165.
51. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KY: Biophysical characterization of recombinant Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry (2001) 40(16):4911-4922.
52. Manion MK, Fry JS, Hockenbery DM: High-throughput methods to identify Bcl-2 family 'gain of function' inhibitors. Cold Spring Harbor Laboratory Programmed Cell Death Meeting (2005):Abs 127.
53. L function. J Biol Chem (2003) 278(23):20453-20456.
54. L that are not the classic BH3 binding cleft. J Mol Biol (2000):doi:10.1016/ j.jmb.2006.09.023.
55. Grenby TH: The use of sangulnarine in mouthwashes and toothpaste compared with some other antimicrobial agents. Br Dent J (1995) 178(7):254-258.
56. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Auged DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 435(7042):677-681.
57. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC et al: Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem (2006) 49(3):1165-1181.
58. L potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 66(17):8731-8739.